-
公开(公告)号：US20240024338A1
公开(公告)日：2024-01-25
申请号：US18334738
申请日：2023-06-14
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao. , Xiaochun Lou , Sean Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff G. Zhang
CPC classification number: A61K31/661 , A61K9/0019 , A61K9/14 , A61K45/06 , A61K9/08 , C07F9/12
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US20130345255A1
公开(公告)日：2013-12-26
申请号：US13922442
申请日：2013-06-20
Applicant: AbbVie Inc.
Inventor： Arthur Gomtsyan , Jerome Daanen , Michael E. Kort , Philip R. Kym , Eric A. Voight , Kevin R. Woller
IPC: C07C317/28 , A61K31/192 , A61K31/353 , A61K31/436 , A61K31/352 , C07D311/96 , C07D491/052 , A61K31/18 , C07D311/68
CPC classification number: C07C317/28 , A61K31/18 , A61K31/192 , A61K31/352 , A61K31/353 , A61K31/436 , C07C311/08 , C07C2602/08 , C07D263/48 , C07D311/68 , C07D311/96 , C07D401/04 , C07D417/12 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，前药或其组合，其中X1，L，Rx，Ry，Rz，R1，R2，A，m，n，p，q和r定义在 规格。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US20200262852A1
公开(公告)日：2020-08-20
申请号：US16866400
申请日：2020-05-04
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla E. Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff Zhang
IPC: C07F9/09 , A61K45/06 , A61K31/6615 , C07C47/277 , C07C309/24 , C07C281/02 , C07F9/06 , A61K31/661
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US08796328B2
公开(公告)日：2014-08-05
申请号：US13922442
申请日：2013-06-20
Applicant: AbbVie Inc.
Inventor： Arthur Gomtsyan , Jerome Daanen , Michael E. Kort , Philip R. Kym , Eric A. Voight , Kevin R. Woller
CPC classification number: C07C317/28 , A61K31/18 , A61K31/192 , A61K31/352 , A61K31/353 , A61K31/436 , C07C311/08 , C07C2602/08 , C07D263/48 , C07D311/68 , C07D311/96 , C07D401/04 , C07D417/12 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I) or pharmaceutically acceptable salts, prodrugs, or combinations thereof, wherein X1, L, Rx, Ry, Rz, R1, R2, A, m, n, p, q, and r are defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）化合物或其药学上可接受的盐，前药或其组合，其中X1，L，Rx，Ry，Rz，R1，R2，A，m，n，p，q和r定义在 规格。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US11091507B2
公开(公告)日：2021-08-17
申请号：US16866400
申请日：2020-05-04
Applicant: AbbVie Inc.
Inventor： Brian P. Enright , Ye Huang , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Peter T. Mayer , Christopher P. Miller , Valentino J. Stella , Eric A. Voight
IPC: C07F9/09 , A61K31/661 , C07F9/06 , C07C281/02 , C07C309/24 , C07C47/277 , A61K31/6615 , A61K45/06
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
Patent Agency Ranking
公开(公告)号：US08969325B2
公开(公告)日：2015-03-03
申请号：US13716862
申请日：2012-12-17
Applicant: AbbVie Inc.
Inventor： Michael J. Dart , Philip R. Kym , Eric A. Voight , Anurupa Shrestha , Jerome F. Daanen , Tammie K. Jinkerson , Ryan G. Keddy , Sridhar Peddi , Arthur Gomtsyan , Michael E. Kort , Gregory A. Gfesser , Kevin R. Woller , Derek W. Nelson
IPC: C07D405/12 , C07D215/38 , C07D239/80 , C07D413/12 , C07D491/052 , A61K31/192 , A61K31/4704 , A61K31/4709 , A61K31/517 , A61K31/538 , A61K45/06 , C07D413/14 , C07D215/227 , C07D265/36
CPC classification number: C07D405/12 , A61K31/192 , A61K31/4704 , A61K31/4709 , A61K31/517 , A61K31/538 , A61K45/06 , C07D215/227 , C07D215/38 , C07D239/80 , C07D265/36 , C07D413/12 , C07D413/14 , C07D491/052
Abstract: Disclosed herein are compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein X1, L, Rx, Ry, G, Z, A, m, n, and p are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also disclosed.
Abstract translation: 本文公开了式（I）的化合物或其药学上可接受的盐，其中X1，L，Rx，Ry，G，Z，A，m，n和p如说明书中所定义。 还公开了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和病症的方法。
-
公开(公告)号：US20140080803A1
公开(公告)日：2014-03-20
申请号：US13658355
申请日：2012-10-23
Applicant: ABBVIE INC.
Inventor： Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt , Eric A. Voight
IPC: A61K31/505 , A61K31/4418 , C07D213/34 , C07D213/38 , A61K31/444 , C07D239/26 , A61K31/4433 , C07D401/06 , A61K31/4427 , C07D405/08 , A61K31/443 , C07D417/08 , A61K31/4439 , A61K45/06 , A61K31/192 , C07D213/30
CPC classification number: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
Abstract: Disclosed herein are modulators of TRPV3 of Formula (I) wherein p is 1, 2, 3, or 4, and G1, X1, X2, X3, X4, X5, G2, Z1, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式（I）的TRPV3的调节剂，其中p为1,2,3或4，并且G1，X1，X2，X3，X4，X5，G2，Z1，Ra，Rb和u如 规格。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号：US20130131036A1
公开(公告)日：2013-05-23
申请号：US13658374
申请日：2012-10-23
Applicant: AbbVie Inc.
Inventor： Erol K. Bayburt , Bruce Clapham , Phil B. Cox , Jerome F. Daanen , Michael J. Dart , Gregory A. Gfesser , Arthur Gomtsyan , Michael E. Kort , Philip R. Kym , Robert G. Schmidt , Eric A. Voight
IPC: A61K31/435 , A61K31/444 , C07D239/26 , A61K31/505 , C07D405/10 , A61K31/4433 , C07D405/06 , A61K31/443 , A61K31/4427 , C07D213/72 , C07D401/06 , A61K31/4545 , C07D215/14 , A61K31/47 , C07D221/04 , A61K31/4439 , A61K45/06 , C07D213/30
CPC classification number: C07D213/38 , A61K31/192 , A61K31/435 , A61K31/4418 , A61K31/4427 , A61K31/443 , A61K31/4433 , A61K31/4439 , A61K31/444 , A61K31/4545 , A61K31/47 , A61K31/505 , A61K45/06 , C07D213/30 , C07D213/34 , C07D213/72 , C07D215/14 , C07D221/04 , C07D239/26 , C07D311/04 , C07D401/06 , C07D405/06 , C07D405/08 , C07D405/10 , C07D417/08 , A61K2300/00
Abstract: Disclosed herein are modulators of TRPV3 of formula (II): wherein G1, X1, X2, X3, X4, X5, G2, Ra, Rb, and u are as defined in the specification. Compositions comprising such compounds and methods for treating conditions and disorders using such compounds and compositions are also presented.
Abstract translation: 本文公开了式（II）的TRPV3的调节剂：其中G1，X1，X2，X3，X4，X5，G2，Ra，Rb和u如说明书中所定义。 还提出了包含这些化合物的组合物和使用这些化合物和组合物治疗病症和障碍的方法。
-
公开(公告)号：US20220153765A1
公开(公告)日：2022-05-19
申请号：US17378321
申请日：2021-07-16
Applicant: AbbVie Inc.
Inventor： Benoit Cardinal-David , Vincent S. Chan , Kassibla Dempah , Brian P. Enright , Rodger F. Henry , Raimundo Ho , Ye Huang , Alexander D. Huters , Russell C. Klix , Scott W. Krabbe , Philip R. Kym , Yanbin Lao , Xiaochun Lou , Sean E. Mackey , Mark A. Matulenko , Peter T. Mayer , Christopher P. Miller , James Stambuli , Valentino J. Stella , Eric A. Voight , Zhi Wang , Geoff G. Zhang
IPC: C07F9/09 , A61K31/661 , C07F9/06 , C07C281/02 , C07C309/24 , C07C47/277 , A61K31/6615 , A61K45/06
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
公开(公告)号：US10730895B2
公开(公告)日：2020-08-04
申请号：US16210996
申请日：2018-12-05
Applicant: AbbVie Inc.
Inventor： Philip R. Kym , Eric A. Voight
IPC: C07F9/09 , A61K31/661 , C07F9/06 , C07C281/02 , C07C309/24 , C07C47/277 , A61K31/6615 , A61K45/06
Abstract: The present disclosure relates to (a) carbidopa prodrugs, (b) pharmaceutical combinations and compositions comprising a carbidopa prodrug and/or an L-dopa prodrug, and (c) methods of treating Parkinson's disease and associated conditions comprising administering a carbidopa prodrug and an L-dopa prodrug to a subject with Parkinson's disease.
-
-
-
-
-
-
-
-
-
Search Results
20
records
(took 0.029 seconds)
